← Eichor
Study identifier: NCT07207369 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

Condition: Acne Scars  ·  Sponsor: AbbVie

PhasePhase 3
Planned participants395
Who can joinAll sexes, 22 Years to no upper limit
Healthy volunteersNo

About this study

Atrophic acne scars are flat, indented or with an inverted center scars that develop at the endpoint of the normal healing process for acne. Acne scarring that remains after acne resolves has a significant impact on health related quality of life, including reduced self-esteem and embarrassment/self consciousness. ELAPR002f provides an immediate space-occupying effect for filling in the scar tissue. The purpose of this study is to assess how safe and effective ELAPR002f injectable gel is on adult participants with atrophic acne scars. ELAPR002f injectable gel is an investigational device being developed for the treatment of facial atrophic acne scars. There are 2 cohorts in this study. In Cohort 1, all participants will receive ELAPR002f injectable gel. In Cohort 2, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to the saline active control group. Around 395 adult participants with moderate to severe atrophic acne scarring on both cheeks will be screened in the study in approximately 25 sites in the United States. Participants will receive 3 treatments over 2 months of intradermal injections of either ELAPR002f injectable gel or saline active control and will be followed for up to an additional 12 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during …

This description comes directly from the study's public registry record.

Talk to the study team

ABBVIE CALL CENTER  ·  844-663-3742  ·  abbvieclinicaltrials@abbvie.com

Always discuss trial participation with your own doctor first.

Locations (10)

Advanced Research Associates - Glendale /ID# 254961Glendale, Arizona, United StatesRecruiting
Marcus Facial Plastic Surgery /ID# 275880Redondo Beach, California, United StatesRecruiting
Pacific Clinical Innovations /ID# 256185Vista, California, United StatesRecruiting
DMR Research PLLC /ID# 256199Westport, Connecticut, United StatesRecruiting
Hamilton Research, LLC /ID# 256925Alpharetta, Georgia, United StatesRecruiting
Aesthetic Center at Woodholme /ID# 256197Baltimore, Maryland, United StatesRecruiting
The Center for Dermatology Cosmetics & Laser Surgery /ID# 256182Mount Kisco, New York, United StatesRecruiting
Wilmington Dermatology Center /ID# 256192Wilmington, North Carolina, United StatesRecruiting
Austin Institute for Clinical Research - Pflugerville /ID# 256200Pflugerville, Texas, United StatesRecruiting
SkinDC /ID# 254962Arlington, Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07207369